Clinical Trial Update: A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 [Phase 1]

View source ↗

Summary

Phase 1 extension results from a single-dose trial of the recombinant Factor VIII (N8) in Japanese subjects with Haemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• N8 recombinant Factor VIII (Factor VIII, recombinant)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED